Healthcare entity
Every one of those 2 sits in a single category, market-trends. Borrelia burgdorferi is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Across a 131-day span, the pace is roughly 0.1 stories per week. Source depth averages 1.5 original sources per story, versus 4.8 across the same-window beat baseline.
Last mentioned: Aug 2, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, market-trends. Borrelia burgdorferi is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Across a 131-day span, the pace is roughly 0.1 stories per week. Source depth averages 1.5 original sources per story, versus 4.8 across the same-window beat baseline. The 6 average consequence score is below the beat benchmark of 6.4 in the same window. This profile follows 2 Healthcare stories mentioning Lyme disease across the period from March 25, 2026 to August 2, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 327 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Lyme disease. Shared-story counts are live from our verified record — not editorial picks.
Regulatory Submission
Anticipated filing for FDA and EMA approval based on final trial data.
Efficacy Milestone
Trial results indicate efficacy exceeding the 70% threshold.
Phase 3 Launch
The VALOR trial begins enrolling thousands of participants in endemic areas.
Partnership Formed
Pfizer and Valneva enter a collaboration agreement to develop VLA15.
With CDC data showing record ER visits for tick bites and an estimated half-million annual Lyme infections, healthcare providers must sharpen diagnostic vigilance and public messaging. The disease’s stealthy onset and severe long-term sequelae demand proactive screening, particularly in endemic regions.
Source: mercurynews.com
Pfizer and Valneva have announced that their Lyme disease vaccine candidate, VLA15, demonstrated more than 70% efficacy in late-stage clinical trials. This breakthrough marks the first successful human vaccine development for the tick-borne illness in over two decades, addressing a critical gap in public health.
Source: ktbb.com · madrock1025.com
Lyme disease is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
